Australia · Delayed Price · Currency is AUD Artrya Earnings Call Transcripts
Fiscal Year 2026
-
Converted all U.S. foundation partners to commercial contracts, launched first Plaque module revenues, and secured six major SAPPHIRE study sites. Strong cash position of AUD 76.5 million supports FDA submission and U.S. expansion, with full customer ramp-up targeted for FY 2027.
-
Technical integration and commercial negotiations with U.S. partners are progressing, with FDA clearance for the Salix Coronary Plaque module and a strong $80 million capital raise supporting U.S. expansion. Cash outflows rose due to scaling, but the company remains well-funded and targets break-even by FY2027.
Fiscal Year 2025
-
A real-time, AI-driven coronary CT platform is set to transform cardiac care by streamlining hospital workflows, improving patient outcomes, and delivering strong financial returns. With foundation customers committed and a robust U.S. go-to-market plan, break-even is targeted by FY2027.
-
The AGM highlighted a successful transition to commercial operations, strong U.S. market entry, and robust financial planning. Key FDA clearances, strategic partnerships, and a focus on high-margin SaaS growth were discussed, with profitability targeted for FY 2027-2028.
-
FDA clearance of the Salix Coronary Plaque Module enables real-time, automated plaque analysis, positioning the platform for rapid U.S. adoption and significant revenue growth. The company is focused on structured hospital rollouts, expanding clinical studies, and further product development.
-
Transitioning to commercial operations, the company secured its first U.S. deal and is expanding partnerships in both the U.S. and Australia. FDA clearance for the plaque module and the SAPPHIRE study launch are key near-term priorities, with strong market interest and a solid cash position.
-
FDA clearance for the SCA product enables U.S. market entry and platform expansion, supported by a strong capital position and key customer agreements. SAPPHIRE study and U.S. commercialization efforts target significant scan volumes, with break-even expected in FY 2026 and cash flow positive in FY 2027.
-
FDA clearance for Salix Coronary Anatomy enables rapid U.S. market entry and sets the stage for future product approvals. Strategic partnerships and clinical studies are advancing, with break-even projected in FY26 and a focus on point-of-care differentiation.
-
Quarterly spend was reduced while maintaining momentum on FDA submissions, with clearance for the lead product expected by March and additional products in the pipeline. U.S. market integration is advancing, supported by a recent AUD 5 million capital raise and strong partner validation.
Fiscal Year 2024
-
The meeting highlighted progress toward FDA approval, a successful capital raise, and strategic U.S. partnerships. Shareholders approved all resolutions, and management emphasized a strong focus on U.S. market entry and product differentiation, with robust plans for 2025.